CD8A and neoplasm: Our study yielded a peptide, named L7N, derived from the PD-L1 ectodomain, which exhibited potent ability to block the PD-1-PD-L1 interaction in vitro and in vivo, reinvigorate PD-1-suppressed T cells, and inhibit tumor growth in mice by promoting the tumor recruitment of CD8+ T cells.